ALSO NOTED: Korea fines pharma firms for kickbacks; Medco boosts profits 16 percent;

> Ten Korean drug makers were fined $22 million for illegal rebates to hospitals and wholesalers. Report

> Pharmacy-benefits giant Medco Health Solutions posted a 16 percent hike in third-quarter profits and boosted its year-end earnings outlook again. Report

> Shire boasted a 41 percent increase in sales for the quarter, to $543 million, and raised its prediction for 2007 revenue growth to 30 percent from 25 percent. Release

> Shire also appointed MedImmune CEO David Mott as non-executive director; Mott also is executive vice president of AstraZeneca, which owns MedImmune. Report

> Drugs distributor Amerisource Bergen saw fourth-quarter profits fall 28 percent because of a big writedown on vaccine inventories. Report

> Smith & Nephew reported a 16 percent increase in adjusted earnings per share on a 24 percent increase in revenue to $845 million. Report

> A revolution in genomics and molecular biology has spurred a burst of new development activity in the vaccines business. Report

And Finally... Nematode worms treated with lithium live 46 percent longer. Would humans? Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.